Breast Cancer Research and Treatment

Article	Citations
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	124
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	105
Area deprivation index and breast cancer outcomes among patients in Western New York	69
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer	63
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study	62
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis	54
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	52
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	50
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	43
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study	40
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy	35
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study	35
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience	34
Integrating SENOMAC and AMAROS: a call for de-escalation	33
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients	33
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis	32
Prognostic and predictive impact of NOTCH1 in early breast cancer	31
Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study	31
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	31
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	28
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study	28
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	28
Chronic inflammatory diseases and survival among breast cancer patients in the U.S. military health system	27
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	27
Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study	26

SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast	26
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials	25
Surveillance mammography after treatment for male breast cancer	25
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	24
Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000–2016	24
The feasibility and safety of fasting-mimicking diet in breast cancer patients with chemotherapy in China	24
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	23
Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database	23
Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis	23
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer	23
The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer	23
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers	23
Risk of myocardial infarction and stroke after breast cancer: an analysis of a population of 1.3 million women from North-West Italy	23
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	23
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study	22
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	22
Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?	21
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy	21
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial	21
Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer	21
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study	21
Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea	21
Letter to the Editor in response to paper “BRCA1 promoter methylation in triple-negative breast cancer……” by K Daster et al	21
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry	21
Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients	21
Cost-effectiveness analysis of Mepitel Film for prevention of acute radiation dermatitis in breast cancer: a Canadian healthcare perspective	21
Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis	21
Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies	21
Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis	21
Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer	21
Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations	20
Enhancing surgical precision: active marker localization at the time of biopsy in breast cancer management	20
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study	20
A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer	20
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis	20
Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study	20
Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms	20
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent ki	20
Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer	19
Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception	19
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study	19
Risk factors for postoperative bleeding following breast cancer surgery: a systematic review and meta-analysis	19
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021	19
Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study	19
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy	19
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk	18
Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene	18
Hormone-associated dietary patterns and premenopausal breast cancer risk	18
Clinical trials of immunotherapy in triple-negative breast cancer	18
Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis	18

Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017	18
Telehealth utilization during the COVID-19 pandemic: comparing breast cancer survivors to non-cancer patients and implications for current practice	18
Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population	18
Correction: Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019	18
Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients	17
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group’s (DBCG) NAME-trial	17
Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study	17
Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma	17
A nomogram for predicting in-breast tumor recurrence risk in breast cancer patients treated with partial breast irradiation using intraoperative electron radiation therapy	17
Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics	17
Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients	17
Influence of tumour grade on disease survival in male breast cancer patients: a systematic review	17
Multi-omics portrait of ductal carcinoma in situ in young women	16
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study	16
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial	16
Side effects and adherence trajectories of adjuvant endocrine therapy in breast cancer patients: results from the VICAN2 study	16
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer	16
Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer	16
APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis	16
Strict definition of a small tumor in breast cancer should be revisited	16
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world	16
Clinical and sociodemographic determinants of older breast cancer survivors’ reports of receiving advice about exercise	16
Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction	15
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?	15
A mixed method study of medical oncologists’ perceived barriers and motivators to addressing long-term effects in breast cancer survivors	15
Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany	15
Double-negative T cells with a distinct transcriptomic profile are abundant in the peripheral blood of patients with breast cancer	15
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer regist	15
Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status	15
Social inequalities in the use of physiotherapy in women diagnosed with breast cancer in Barcelona: DAMA cohort	15
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer	15
Overview of ocular toxicities associated with breast cancer therapies	15
Impact of public vs. private insurance coverage on quality of life of women with early-stage estrogen receptor-positive breast cancer	15
HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles	15
A novel role of IGFBP5 in the migration, invasion and spheroids formation induced by IGF-I and insulin in MCF-7 breast cancer cells	15
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study	15
Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer	14
Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis	14
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)	14
Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy—results of the multicenter UMBRELLA breast cancer cohort	14
Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases	14
Letter to the editor regarding “Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany”	14
Correlation analysis between shear-wave elastography and pathological profiles in breast cancer	14
Male breast cancer: a multicenter study to provide a guide for proper management	14
Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients	14
Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263	14
Re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)	14
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer	14
Omission of multimodal therapy in older adults with high-risk breast cancer	14
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice	14
Digital mammography and digital breast tomosynthesis for detecting invasive lobular and ductal carcinoma	14
Association between body mass index and outcomes after autologous breast reconstruction: a nationwide inpatient database study in Japan	14
Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases	14
A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast	13
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial	13
Correction: Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics	13
Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy	13
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium	13
Changes in the survival of patients with breast cancer: Poland, 2000–2019	13
Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and	13
ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors	13
The relationship between impaired upper-body function, quality of life and breast cancer-related lymphoedema: results from a prospective, population-based cohort study	13
Promoting Resilience in Stress Management (PRISM) for women with breast cancer: a qualitative analysis of patient impressions and recommendations	13
Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study	13
Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database	13
Multi-level factors drive use of sentinel lymph node biopsy in older women with early-stage breast cancer	13
Single-institution outcomes after excision of benign phyllodes tumors: low recurrence risk even with positive margins	13
Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer	13
Letter to editor on the article by K.‑H. Yoon et al., titled Impact of obesity on breast cancer recurrence by menopausal status and subtype	13
Association of body composition and surgical outcomes in patients with early-stage breast cancer	13
Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit	13
Worse survival despite indolent features for triple-negative invasive lobular carcinoma: a Swedish nationwide registry-based study	13
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials	13
High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors	13
Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center	13
Quantifying radiation in the axillary bed at the site of lymphedema surgical prevention	13
Organoid models derived from patients with malignant phyllodes tumor of the breast	13
Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome	12
Correction: The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection	12
Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age	12

Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting	12
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer	12
Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study	12
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer	12
Burden and trajectory of social needs after breast cancer diagnosis at a safety-net hospital	12
Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors	12
Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis	12
Limitations of locoregional and distant recurrence analysis after neoadjuvant chemotherapy	12
Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer	12
The importance of SOCS1 − 1478 CA/del polymorphism and expression in breast cancer: a case–control study in the north of Iran	12
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer	12
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer	12
Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis	12
Reply to: “Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)”	12
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers	12
Lumpectomy surgery for large ductal carcinoma in situ	12
Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases	12
Adverse effects of scalp cooling for the reduction of chemotherapy-induced alopecia: A systematic review and meta-analysis	12
Correction: mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo	12
Factors associated with breast cancer detection method in California women: an analysis of California Health Interview Survey data	12
BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors	12
Diagnostic performance of screening mammography according to menstrual cycle among Asian women	12
High-resolution microCT to assess breast microcalcification morphometry by histologic lesion subtype and radiologic classification	11
Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients	11
Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy	11
HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series	11
Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review	11
Severe hyponatremia with abemaciclib use in the absence of pre-existing renal disease	11
Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics	11
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41	11
The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study	11
The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis	11
BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses	11
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy	11
The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey	11
Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in ZEB1 expression	11
Is axillary web syndrome a risk factor for breast cancer-related lymphedema of the upper extremity? A systematic review and meta-analysis	11
Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi	11
Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study	11
A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1–CDK4 interaction	11
Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study	11
Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review	11
Estimating the incidence of breast cancer recurrence using administrative data	11
Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis	11
Perceptions of breast cancer risk after breast density notification in a population-based screening program	11
Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study	11
Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project	11
Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution	11
USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells	10
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?	10
The impact of breast cancer treatment on sleep disturbance: a systematic review	10
Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study	10
Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	10
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer	10
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy	10
COVID-19 related change in breast cancer diagnosis, stage, treatment, and case volume: 2019–2021	10
Molecular characterization of ESR1 variants in breast cancer	10
Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center	10
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer	10
Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression	10
Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer	10
Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment	10
Chronic skin toxicities in breast cancer survivors: a systematic review and meta-analysis of radiotherapy techniques	10
Stalled at the intersection: insurance status and disparities in post-mastectomy breast reconstruction	10
Impact of analysis of the sentinel lymph node by one-step nucleic acid amplification (OSNA) compared to conventional histopathology on axillary and systemic treatment: data from the Dutch nationwide c	10
Molecular Dynamics of Breast Cancer Subtypes: The Role of FAM83H-AS1 Long Non-coding RNA in Breast Cancer Metastasis	10
Long-term benefits of exercise interventions during chemotherapy in breast cancer: insights from the optitrain trial calling for longitudinal studies	10
Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors	10
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer	10
The association between age at breast cancer diagnosis and prevalence of pathogenic variants	10
Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer	10
Clinico–pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis	10
Relationship between oily fish intake and breast cancer based on estrogen receptor status: a Mendelian randomization study	10
Does a brief surgeon training in negotiation theory principles decrease rates of contralateral prophylactic mastectomy?	10
Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study	10
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-	10
Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction	10
Impact of diabetes on surgery and radiotherapy for breast cancer	10
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study	10
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, car	10
Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study	10
Neoadjuvant systemic therapy in geriatric breast cancer patients: a National Cancer Database (NCDB) analysis	10
First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer	10
Reply to Bourgeois P.	10
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy	10
Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique	10
Factors associated with receipt of surveillance breast MRI among racially and ethnically diverse women with operable breast cancer	9
A single bout of resistance or high-intensity interval training increases anti-cancer myokines and suppresses cancer cell growth in vitro in survivors of breast cancer	9
Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis	9
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer	9
Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care	9
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database	9
Cardiotoxicity among socioeconomically marginalized breast cancer patients	9
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer	9
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor	9